

AMENDMENTS TO THE CLAIMS

Please amend claims 1 and 4-13.

Please cancel claim 14 without prejudice.

1. (Currently Amended) A hybrid artificial blood vessel comprising a biodegradable polymer-supporting layer on at least one of an inside and an outside of a non-degradable artificial blood vessel layer, wherein the biodegradable polymer-supporting layer is porous and the porous space of the biodegradable polymer-supporting layer is artificially formed by using porogen, and wherein a drug is stored in at least one region selected from the group consisting of the microporous space of the non-degradable artificial blood vessel layer, and the porous space of the biodegradable polymer-supporting layer, and the interface of drug is degraded from the non-degradable artificial blood vessel layer and the biodegradable polymer-supporting layer with the passage of time to generate new vascular tissues.

2. (Original) The hybrid artificial blood vessel as claimed in claim 1, wherein the biodegradable polymer comprises at least one polymer selected from the group consisting of synthetic polymers such as polyglycolide, polylactide, poly(lactic-co-glycolic acid) and polycaprolactone, or natural polymers such as chitosan, gelatin, alginic acid, hyaluronic acid and collagen.

3. (Original) The hybrid artificial blood vessel as claimed in claim 1, wherein the non-degradable artificial blood vessel layer comprises polyurethane derivatives, DacronR or drawn polytetrafluoroethylene.

54. (Currently Amended) The hybrid artificial blood vessel as claimed in claim 1, wherein the drug comprises at least one selected from the group consisting of vascular endothelial growth factor, fibroblast growth factor, nerve growth factor, platelet-derived growth factor, heparin, thrombin, laminin, fibronectin and collagen.

65. (Currently Amended) The hybrid artificial blood vessel as claimed in claim 1, wherein the biodegradable polymer supporting layer is porous the drug is further stored in the

interface of the artificial blood vessel layer and the porous biodegradable polymer-supporting layer.

76. (Currently Amended) The hybrid artificial blood vessel as claimed in claim 1, wherein the biodegradable polymer-supporting layer is repetitively coated on the artificial blood vessel layer.

87. (Currently Amended) The hybrid artificial blood vessel as claimed in claim 1, wherein the surface of the non-degradable artificial blood vessel layer is modified physically or chemically.

98. (Currently Amended) A manufacturing process of a hybrid artificial blood vessel, comprising the steps of: dissolving biodegradable polymer in organic solvent to prepare biodegradable polymer solution A; adding porogen to the polymer solution A; dissolving the same or different biodegradable polymer with the above biodegradable polymer in organic solvent to prepare biodegradable polymer solution B; incorporating the biodegradable polymer solution B into micropores of an artificial blood vessel layer; inserting tubes to the inside and outside of the artificial blood vessel layer; filling the biodegradable polymer solution A in a space between the artificial blood vessel layer and the tubes; drying the artificial blood vessel layer filled with the biodegradable polymer solution A to remove the organic solvent; and incubating the artificial blood vessel layer filled with the biodegradable polymer solution A in a water bath to remove the porogen.

102. (Currently Amended) The manufacturing process as claimed in claim 8, wherein the biodegradable polymer comprises at least one polymer selected from the group consisting of polyglycolide, polylactide, poly(lactic-co-glycolic acid), chitosan, gelatin, alginic acid and collagen.

110. (Original) The manufacturing process as claimed in claim 8, wherein the non-degradable artificial blood vessel layer comprises polyurethane derivatives, DacronR or drawn polytetrafluoroethylene.

~~12~~11. (Currently Amended) The manufacturing process as claimed in claim 8, wherein the biodegradable polymer solutions A and B further comprise a drug which contains growth factors or extracellular matrices.

~~13~~12. (Currently Amended) The manufacturing process as claimed in claim 11, wherein the drug comprises at least a drug selected from the group consisting of vascular endothelial growth factor, fibroblast growth factor, nerve growth factor, platelet-derived growth factor, heparin, thrombin, laminin, fibronectin and collagen.

~~14~~13. (Currently Amended) The manufacturing process as claimed in claim 8, wherein the surface of the non-degradable artificial blood vessel layer is modified physically or chemically.

~~15~~14. (Canceled)